Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maintenance Lenalidomide Therapy After Autologous Stem Cell Transplant in Patients With High Risk Relapsed/Refractory Lymphomas

NCT01575860 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT01575860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01575860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maintenance Lenalidomide Therapy After Autologous Stem Cell Transplant in Patients With High Risk Relapsed/Refractory Lymphomas
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2012
Completion date
October 31, 2022
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma